Executive summary. Moving medical cannabis across borders requires more than a commercial invoice and a GMP certificate. Each shipment may involve a licensed exporter, licensed importer, controlled-drug import and export permits, customs documentation, quality release responsibilities and transport conditions. The precise route depends on origin, destination, product classification and whether the material is a starting material, active substance or finished medicinal product.
Map the legal status of the material
The first step is to define what is being shipped. Dried flower, bulk extract, isolated cannabinoid and finished medicine may fall under different medicines, customs and controlled-drug requirements. The same material may be classified differently at origin and destination.
Confirming the legal status of the specific material — not just "cannabis" as a general category — is the necessary first step, since narcotics scheduling, THC threshold and product classification each affect which import route applies.
Activity licences and shipment permits
The exporter and importer need the appropriate national activity licences. Controlled substances commonly require a separate permit for each shipment. The import permit is often obtained first and used to support the export permit application. Quantity, batch, strength, route and consignee details must match.
Activity licences and shipment permits must be secured on both the export and import side before physical movement begins; missing a permit on either side typically halts the shipment at the border rather than allowing later remediation.
GMP and quality evidence
The importer should confirm that the manufacturer operates to the standard required in the destination market. Evidence may include GMP certificates, inspection reports, manufacturing authorisations, batch documentation and technical agreements. A foreign GMP certificate is not automatically accepted in every situation.
GMP and quality evidence accompanying an import should include the actual GMP certificate reference verifiable in EudraGMDP, not merely a supplier statement of compliance, since national authorities will check the certificate directly.
Third-country imports
Imports from outside the EEA may require additional certification and batch-release steps. The Qualified Person or responsible release function must have access to sufficient evidence. Mutual-recognition arrangements can affect reliance on inspections but do not remove product and controlled-drug requirements.
Third-country imports face additional scrutiny because the exporting country’s regulatory framework may not align with EU GMP expectations, making import certificate review and facility inspection history especially important.
Transport, security and GDP
The transport route should protect temperature, humidity, security and traceability. Cannabis flower may be sensitive to moisture and odour loss; oils may require light and temperature protection. Deviations, theft, tampering and customs delays should be anticipated.
Transport security and GDP compliance during international shipment should address narcotics security requirements alongside standard cold-chain and handling controls, since cannabis shipments are subject to both regimes simultaneously.
Customs and documentation
Commodity codes, invoices, packing lists, licences, permits, certificates of analysis and airway bills must be consistent. Customs clearance does not constitute pharmaceutical release. Conversely, quality release cannot legalise a shipment that lacks controlled-drug permission.
Customs and documentation errors are a common cause of shipment delay; the paperwork trail should be reconciled against the actual physical shipment before it departs, not corrected retrospectively at the border.
Importer quality oversight
The importer should qualify the supplier, approve specifications, review changes and manage complaints, recalls and deviations. Importation is not merely a logistics function. It is part of the pharmaceutical supply chain.
Importer quality oversight does not end at customs clearance — the importing quality system remains responsible for verifying that the received material matches its documentation before it enters further manufacturing or distribution.
Practical reference table
| Document/control | Purpose | Common failure |
|---|---|---|
| Activity licence | Authorises company activity | Wrong scope or site |
| Import permit | Authorises incoming quantity | Mismatch with batch/strength |
| Export permit | Authorises dispatch | Issued before matching import permit |
| GMP evidence | Supports manufacturing compliance | Not accepted by destination authority |
| Quality agreement | Assigns responsibilities | No change or deviation notification |
| Transport qualification | Protects shipment | Customs delay not considered |
Decision and implementation path
Common implementation mistakes
Common mistakes include choosing a country because cultivation appears attractive without confirming product access; assuming that GMP certification resolves controlled-drug permissions; using broad cannabis terminology where the active substance is not clearly defined; and relying on commercial claims that exceed the available evidence. A second recurring weakness is treating laboratories, logistics providers or cultivators as external to the pharmaceutical quality system. Outsourced work remains part of the regulated supply chain and requires qualification, agreements, performance review and change notification.
Frequently asked questions
Is one permit enough for repeated shipments?
Often not. Many controlled-drug systems require shipment-specific permits.
Does customs clearance mean the batch is released?
No. Customs and pharmaceutical release are separate.
Can any EU GMP certificate be accepted automatically?
Acceptance depends on the authority, issuing body, product scope and import route.
Who investigates a transport excursion?
Responsibilities should be defined between exporter, carrier and importer, with the importer assessing destination-market impact.
Can flower be imported before final packaging?
Potentially, if the licensed activities and quality arrangements permit it.
Primary references and guidance
- United Nations Single Convention on Narcotic Drugs
- EU GMP Guide
- EU GDP Guidelines
- EMA guidance on GMP/GDP and third-country manufacture
- BfArM import/export requirements under MedCanG
- INFARMED controlled-substance and cannabis licensing information
- National import/export permit requirements
- Technical agreements under EU GMP Chapter 7
Confirm the current effective version and national applicability before operational, medical or regulatory use.